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I. AIMS AND OBJECTIVES
The main objectives of the study are as follows:
1. To study the prevalence of Hypothyroidism (Clinical/Subclinical) in
Diabetic patients
2. To study the correlation of HbA1c levels with TSH levels
II. MATERIALS AND METHODS
PLACE OF STUDY
Stanley Medical College and Hospital, Chennai:
Department of General Medicine, Endocrinology OPD, Medical wards
SAMPLE SIZE: 50
DURATION
February 2014 - September 2014.
STUDY DESIGN
Prospective Observational Study
ETHICAL COMMITTEE APPROVAL
Ethical committee approval was obtained for the study
PATIENT SELECTION
Inclusion Criteria:
1. Any patient coming with history of type 2 Diabetes Mellitus of more
than 3 years duration with or without Hypothyroidism.
2. Any patient on treatment for Hypothyroidism with history of type 2
Diabetes.
Exclusion Criteria:
1. Patients with type 2 Diabetes Mellitus for less than 3 years duration.
2. Patients in Hyperglycaemic emergencies.
3. Patients with pervious history of Thyroid surgery.
METHODOLOGY
Patients coming with history of type 2 diabetes mellitus with or without history
hypothyroidism of more than 3 years duration or patients on treatment for
hypothyroidism with history of diabetes mellitus presenting to OPDs or
admitted in wards from February 2014 to September 2014 are included in the
study. Patients are subjected to symptom analysis, clinical examination, blood
investigations including HBA1C and TSH levels. The newly diagnosed patients
of hypothyroidism in diabetes were treated with thyroxine for three months and
followed up with TSH and HBa1c levels.
III. CONCLUSION
Diabetes Mellitus and hypothyroidism are very closely related to each other and
both are associated with several metabolic abnormalities. There are many
common features in both these endocrine disorders.
The normalization of TSH levels leads to a reduction in postprandial glucose
levels, CRP, HbA1c and lipids. This indicates a significant effect of treatment
with L-thyroxine on glycemic control in patients with subclinical
hypothyroidism.
Determination of TSH is accurate, accessible, safe and inexpensive test to
diagnose subclinical hypothyroidism. Determining the level of TSH can be used
to define the risk of the occurrence of various complications (osteoporosis,
cardiovascular disease, depression) for different intervals between TSH.
Subclinical hypothyroidism is quite hard to diagnose. In practice this is often
overlooked. Adequate diagnosis requires conducting extensive laboratory tests
other than routine as the TSH test. Monitoring of body temperature and careful
monitoring of clinical signs, then well taken case history helps to faster and
easier detection of this disease in medical practice.
My study revealed a strong correlation between duration of diabetes and
hypothyroidism, FBS values and hypothyroidism.Hba1c before and after
thyroxine, TSH before and after thyroxine also revealed a strong
correlation(p<.05).The main part of my study which revealed a strong
correlation between Hba1c and TSH levels.
As per the previous studies (as in citations) and my study, I can conclude that
there was high prevalence of hypothyroidism in diabetes mellitus and there was
correlation between Hba1c and TSH levels.
More studies with similar indices have to be performed to confirm the study
results. I can also conclude that doing a TSH levels in patients of diabetes
mellitus is warranted.
KEY WORDS: Hypothyroidism, subclinical hypothyroidism, Diabetes
mellitus,Hba1c, fasting blood sugar, TSH, thyroxine.
1I. INTRODUCTION
Diabetes and hypothyroidism are common metabolic disorders. Both diabetes
and hypothyroidism are interrelated.The hallmarks of hypothyroidism are
decreased absorption of glucose from the intestinal tract along with increased
accumulation of glucose in the periphery with decreased glucose production
from the liver and decreased use of glucose. For those who have subclinical or
overt hypothyroidism, insulin resistance causes glucose stimulated increase in
insulin secretion. Moreover those with subclinical hypothyroidism have an
independent risk for insulin resistance especially in the muscle and adipose
tissue. There is a definite link between hyperinsulinemia, resistance to insulin
and subclinical hypothyroidism. There are numerous mechanisms through
which subclinical hypothyroidism and insulin resistance causes derangement of
glycemic control. Thus the significance of treating subclinical hypothyroid
patients with L thyroxin for better glycaemic control is well indicated. Some
studies have also shown positive effect of metformin therapy in control of
thyroid hormone levels.
2II. REVIEW OF LITERATURE
HISTORICAL REVIEW
Diabetes:
The very first person to give a complete clinical description of diabetes was the
Greek physician Aretaeus of Cappadocia, who found out that patients suffering
from this disease passed increased amount of urine.
Avicenna (930 – 1037) gave a full description about diabetes mellitus in the
book “THE CANON OF MEDICINE” detailing about the increased appetite
and the diminished sexual functions in the patients, and urine of those people
tasting sweet. He recognised primary as well as secondary diabetes just like
Aretaeus before him.
Joseph von Mering and Oskar Minkowski, in 1889, found that when the
pancreas in the dogs was removed, they developed signs and symptoms of
diabetes mellitus and they died soon afterwards. This clearly pointed out the
involvement of pancreas in diabetes mellitus. Sir Edward Albert Sharpey-
Schafer in 1910 postulated that a deficiency of a single chemical which the
pancreas produces is responsible for diabetes—he proposed naming this
chemical insulin, from the Latin insula, which meant island, in reference to
insulin secreting islets of Langerhans in pancreas.3
3Thyroid:
The Chinese people in 1600 BC used seaweed and sponge which was burnt for
the treatment of goitre. Pliny has given an account about the prevalence of an
epidemic of goitre in Alps and mentions the use of burnt seaweed as treatment
for it.
Galen in 150 AD also talks about the use of burnt sponge, spongia-usta, for the
treatment of goitre. He suggested that lubricating the larynx was the major
function of thyroid.
Wang Hei in 1475 described the anatomy of the thyroid gland and said that the
remedy for goitre must be dried goitre. About fifty years later, Paracelsus said
that goitre was due to the mineral impurities present in water. Thomas Wharton
in1656 coined the name of the gland as THYROID meaning SHIELD.
Robert James Graves, doctor of Irish origin published a paper on exophthalmic
goitre.  Exophthalmic goitre is known as Basedow's disease in the European
continent. Karl Adolph Basedow in 1840 had independently described this
entity.
Only in the last century, the idea that thyroid produced an iodine containing
substance was investigated, and Edward Calvin Kendall isolated thyroxine in
1914 as the active principle of thyroid gland.
4THYROID GLAND
Embryology:
The morphogenesis of the thyroid gland, anterior-most organ which buds from
gut tube, begins with thickening of endodermal epithelium in the foregut,
referred to as thyroid anlage. The human thyroid anlage is first recognizable at
embryonic day 16 or 17. This median thickening deepens and forms a small pit
first and then an outpouching of the endoderm adjacent to the developing
myocardial cells.6
The primitive stalk connecting the primordium with the pharyngeal floor
elongates into the thyroglossal duct. During its caudal displacement, the
primordium assumes a bilobate shape, coming into contact and fusing with the
ventral aspect of the fourth pharyngeal pouch when it reaches its final position
at about embryonic day 50.6.6, 7
The thyroglossal duct undergoes dissolution and fragmentation at the second
month after conception, which leaves at the origin a small dimple at the junction
of middle one-third and posterior one-thirds of the tongue called the foramen
caecum. Cells of the lower portion of duct differentiate into thyroid, forming the
pyramidal lobe of the gland. At the same time, the lobes contact the
ultimobranchial glands, leading to conversion of C cells into the thyroid.7, 8
5The histologic alterations occur in the entire gland. Complex, interconnecting,
cord-like arrangements of cells mixed with vascular connective tissue replaces
solid epithelial mass and become tubule-like structures at third month of fetal
life; shortly  after that, follicular arrangements devoid of colloid appear,
following which, at 13 to 14 weeks, the follicles starts to get  filled with
colloid.4
Fig: Evolution of Thyroid gland and its relation to the Branchial Arches
6Fig: Anatomy of the Thyroid gland
7Anatomy:
The thyroid (Greek thyreos, meaning shield, plus eidos, meaning form) is a red-
brown, highly vascular organ located anteriorly at the lower part of the neck,
which extends from the level of 5th cervical vertebra to the 1st thoracic
vertebra.
The gland shape varies from H to U and it overlies the 2nd to 4th tracheal
rings.1, 6 The thyroid is one of the biggest of the endocrine organs, weighing
about 15 to 20 g.
Moreover, the potential of thyroid for growing is tremendous. The enlarged
thyroid, commonly termed a goiter, weighs hundreds of grams. The normal
thyroid is made of two lobes which is joined by a thin band of tissue, the
isthmus, that is approximately 0.5 cm thick, 2 cm wide, and  2 cm high.
The individual lobe normally has pointed superior pole and a poorly defined,
blunt inferior pole that merges medially with the isthmus. Each lobe is about 2.0
to 2.5 cm thick and breadth at its largest diameter is approximately 4.0 cm in
length.
Occasionally, if the remaining part of the gland is enlarged, a pyramidal lobe is
discernible as a finger-like projection directed from the isthmus, usually on the
left, just lateral to the midline. The right lobe is more vascular than the left; it is
8often the bigger of the two and enlarges more in disorders associated with a
diffuse increase in gland size.6, 7
Vascular anatomy:
The thyroid gland is supplied by the superior thyroid and inferior thyroid
arteries and at sometimes by the thyroidea ima artery.7, 8
Estimates of thyroid blood flow range from 4 to 6 mL/minute per gram; well in
excess of the blood flow to the kidney (3 mL/minute per gram).
In diffuse toxic goiter resulting from Graves’ disease, blood flow may exceed 1
L/minute and may be associated with an audible bruit or even a palpable thrill.8
Venous drainage:
The thyroid is drained by three pairs of veins.
 The superior thyroid vein - ascends up with superior thyroid artery and it
becomes a tributary to internal jugular vein.
 The middle thyroid vein - courses lateral to internal jugular vein.
 The inferior thyroid vein - The right passes anterior to innominate artery
to right of brachiocephalic vein. The left drains into the left
brachiocephalic vein.
9At times, both inferior veins join to form a common trunk which is called as the
thyroid ima vein, which drains into left brachiocephalic vein.7, 8
Lymphatic drainage:
The lymph from the thyroid gland flows  to periglandular nodes, prelaryngeal
nodes, pretracheal nodes and paratracheal nodes along with the recurrent
laryngeal nerve  and finally into the mediastinal nodes.7, 8
The major hormones secreted by thyroid gland are thyroxine (T4),
triiodothyronine (T3), and calcitonin. T3 is also formed by de-iodination of T4
in the peripheral tissues. Both T3 and T4 are formed from the same iodine
containing amino acids. Small amounts of reverse triiodothyronine (RT3) are
also formed, which is inactive. T3 is more active than T4.
Naturally occurring forms of T4 are L isomers.1, 6 Of the total metabolically
active hormones produced by the thyroid gland around 93% is T4 and around 7
% is T3. Eventually all the T4 is converted to T3 in the tissues. Even though the
functions of T3 and T4 are qualitatively the same they differ in onset and
intensity of action. T3 is 4 times more potent than T4, but it is present in blood
in much lesser amounts and lasts for shorter duration of time than T4.9
10
Fig: Vascular Anatomy of the Thyroid Gland
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Fig: Physiology of the Thyroid gland
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Iodide Pump (Iodide Trapping):
Transport of I- ions from the blood into the thyroid gland follicles is the first
step in the formation of thyroid hormones. The basal membrane of the thyroid
cell has unique ability to actively pump the iodide into the interior of the thyroid
cell. This is known as iodide trapping.1, 9
Fig: Thyroid gland Histology
Thyroglobulin and Chemistry of Thyroxine and Triiodothyronine
Formation:
Formation and Secretion of Thyroglobulin by the Thyroid Cells
The cells of the thyroid gland are protein producing glandular cells. The
endoplasmic reticulum and Golgi apparatus synthesize and secrete
thyroglobulin a large glycoprotein molecule into thyroid follicle. Thyroglobulin
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has a molecular weight of 335,000. Each one of the molecule of thyroglobulin
has 70 tyrosine amino acids and they combine with iodine to form the thyroid
hormones.  During synthesis of the thyroid hormones, the thyroxine and
triiodothyronine hormones formed from the tyrosine amino acids remain part of
the thyroglobulin molecule
Oxidation of the Iodide Ion
The initial step in the synthesis of the thyroid hormones is conversion of the
iodide ions to the oxidized form which is capable of combining directly with the
amino acid tyrosine. Enzyme peroxidase and hydrogen peroxide promotes the
oxidation of iodide .The peroxidase is attached to  the apical membrane of the
cell and it provides the oxidized iodine at exactly the point in the cell where the
thyroglobulin goes forth from the Golgi bodies and through the cell membrane
into the stored  thyroid gland colloid. Thus when the peroxidase system is
blocked or if it is hereditarily absent the formation of thyroid hormones
becomes nil.9
Iodination of Tyrosine and Formation of the Thyroid Hormones-
“Organification” of Thyroglobulin
The binding of iodine with the thyroglobulin molecule is known as
organification of the thyroglobulin. Oxidized iodine will bind directly but very
slowly with the amino acid tyrosine in molecular form. Oxidized iodine within
14
the thyroid cell is found to be associated with an enzyme called as iodinase that
causes the process to occur within seconds or minutes.
As the thyroglobulin molecule is released from the Golgi apparatus iodine
attaches with around 1/6th of the tyrosine amino acids within the thyroglobulin
molecule.
Tyrosine is first iodized to monoiodotyrosine and then to diiodotyrosine. During
next few minutes, hours, days, more of the iodotyrosine become coupled with
one another. The main hormonal product of coupling reaction is molecule
thyroxine.8
15
Fig: Effects of thyroid hormone on cardiovascular hemodynamics
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Thyroxine remains part of thyroglobulin molecule. One molecule of
monoiodotyrosine couples with another molecule of diiodotyrosine to form
triiodothyronine.
Storage of Thyroglobulin
The thyroid gland stores large amounts of hormone. After synthesis of the
thyroid hormones each thyroglobulin contains up to 30 thyroxine molecules and
a few triiodothyronine molecules. The thyroid hormones are stored in the
follicles in quantities which are sufficient to supply the body for two to three
months.6, 9
Daily Rate of Secretion of Thyroxine and Triiodothyronine
Thyroxine is 93% of the thyroid hormone released from the thyroid and
triiodothyronine is only 7%. In the following days after secretion half of the
thyroxine is slowly de-iodinated to form more of triiodothyronine. Therefore T3
is the major hormone which is finally delivered to the tissues, about 35
micrograms of triiodothyronine per day in our body.9, 10
17
Fig: Regulation of Thyroid Hormone secretion
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Thyroid Hormones Have Slow Onset and Long Duration of Action:
When thyroxine hormone is injected in large quantity it takes about 2-3 days for
its action to begin and hence there is latency before thyroxine action starts.
After its action has begun it increases progressively and it takes around 10 to 12
days for it to reach its peak. After that its action decreases with a t1/2 of about
15 days and some of its activity can be detected even after 12 months. T3 acts
four times faster than thyroxine with a short latent period of 6 to 12 hours and
maximal cellular activity occurring within 2 to 3 days. Binding with proteins
both in the plasma and in the tissue is responsible for its latency and its long
duration of action.
19
Fig: Factors that affect Thyroid function
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Fig: Peripheral actions of the Thyroid hormones
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HYPOTHYROIDISM
Hypothyroidism (Greek, from hypo, under, and thyroid, the gland), often
called underactive thyroid or low thyroid, is an endocrine abnormality which
occurs commonly in which the thyroid gland is not able to produce enough
thyroid hormones.
In overt primary hypothyroidism the TSH levels are high and the T4 &T3 levels
are low.21 It is also diagnosed in those who have a TSH value of greater than
IU/L with symptoms of hypothyroid and borderline T4 values. In persons with a
TSH greater than 10mIU/L it is diagnostic of hypothyroid.21
Subclinical hypothyroidism is a milder form characterized by an elevated serum
TSH level, but a normal serum free thyroxine level.22, 23 In adults it is diagnosed
when TSH levels are greater than 5 mIU/L and less than 10mIU/L.21
Deficiency of iodine is the most common cause of hypothyroidism worldwide.
In those areas in which iodine is sufficient, autoimmune disease (Hashimoto's
thyroiditis) and other iatrogenic causes must be evaluated for.10
22
Fig: Signs and Symptoms of Hypothyroidism
23
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Fig: Signs and Symptoms of hypothyroidism
Laboratory Evaluation:
If the TSH level is normal, then the diagnosis of primary hypothyroidism is
ruled out. If TSH level is elevated, then the level of unbound T4 must be
obtained to confirm clinical hypothyroidism. However as a screening test TSH
is superior to T4 because it will detect subclinical hypothyroidism. Unbound T3
levels are normal in 25% of patients, showing adaptive de-iodinase response to
hypothyroidism; hence measurement of T3 is not indicated.
Once hypothyroidism is diagnosed the presence of TPO antibodies must be
searched to demonstrate the etiology. TPO antibodies are present in about 90%
25
of the patients who suffer from autoimmune hypothyroidism. TBII is found in
10–20% of patients however we do not perform this test routinely.10
Free thyroxine levels in pregnant women will be lower than expected because of
decreased binding of free thyroxine to albumin and because of increased
binding of free thyroxine to thyroid binding globulin. Hence total thyroxine
levels must be used for diagnosis.5 TSH values be less than the normal range in
pregnancy and must be adjusted for the period of pregnancy.5, 19
There is a low sodium level in blood along with raised antidiuretic hormone and
there is as acute worsening of kidney function due to several causes in patients
suffering from very severe hypothyroidism and myxedema coma.
26
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When thyroxine is replaced, it leads to anaemia and other derangements1, 6.
Other laboratory findings which are abnormal in hypothyroidism are anaemia
(usually normocytic or macrocytic), elevated cholesterol and triglycerides and
increased creatine phosphokinase.
28
Treatment:
The decision for treatment with levothyroxine should take into account the
expense and inconvenience of daily medication, which is not acceptable to some
patients, and the possibility of overdose with levothyroxine which can
exacerbate osteoporosis or cause cardiac arrhythmias. Finally, the decision to
treat depends on the careful consideration of the patient’s clinical situation and
preference.18
There are no universally accepted recommendations for the treatment of
subclinical hypothyroidism. Recently published guidelines do not recommend
routine treatment when TSH levels are below 10 mU/L. It is vital to confirm
any elevation of TSH sustained over a three month period and then only
treatment is given.17
Prevention:
By addition of iodine to the food hypothyroidism can be prevented in the large
population. Endemic childhood hypothyroidism has become extinct due to the
addition of iodine to the food. Not only by promoting eating of iodine rich food
like dairy and fish the iodinisation of salt which is done is several countries  has
played a huge role in preventing hypothyroidism.
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DIABETES MELLITUS
There are two types of diabetes. The causes and risk factors for each type are as
follows:
 Type 1 diabetes - in this condition the body produces very little or no insulin.
The patients have to be treated with daily insulin injection. It occurs mainly
in children and young people.
 Type 2 diabetes – it mostly occurs in older people. But now because of
change in lifestyle modifications with more young people being obese the
recent trend is occurrence of type to diabetes in younger age.
Some patients cannot be classified as type 1 or type 2.
Type 2 Diabetes:
It is the most common type of diabetes. It is also called as non insulin dependent
diabetes mellitus.
People who suffer from type to diabetes mellitus make insulin the body. But the
amount of insulin made in the body is insufficient to the demands. This is called
as insulin resistance. Hence the transport of glucose inside the cells is impaired.
So there is increase amount of glucose in the blood and the cells are exposed to
high glucose which is detrimental to the cells in the following ways:
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Damage to the body:
The constantly very high blood glucose levels may cause damage to the blood
vessels and nerves in the eyes, heart, kidney and brain. The blood vessels may
become hardened and atherosclerosis might develop in them eventually
predisposing to myocardial infarction and cerebrovascular accidents.
Dehydration:
The increases blood glucose levels increases the osmolality resulting in
increased urine production causing severe dehydration.
Diabetic coma (hyperosmolar nonketotic diabetic coma):
This is a life threatening complication due to increased blood glucose resulting
in severe dehydration and electrolyte derangements. The patient goes into coma
with negative ketones.
Common symptoms of diabetes:
 Polyuria - increased frequency of micturition
 Polydipsia - increased feeling of thirst
 Polyphagia - increased hunger
 Easy fatigability
 Vision getting blurred
 Slow and poor healing of wounds
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 In hands and feet there is burning tingling sensation due to diabetic
neuropathy19
Diagnosis:
American Diabetes Association says that any of the following can be used for
diagnosis of diabetes:
 HbA1c or glycosylated haemoglobin test
 FPG -a fasting plasma glucose test
 OGTT - an oral glucose tolerance test
The hbA1c levels give an idea about the glucose value during the past 3 months.
It gives a fair idea how treatment is working.18
The haemoglobin is present inside the red blood cells. The function of
haemoglobin is to transport oxygen to the tissues. When the red blood cells are
constantly exposed to high level of blood glucose, the glucose enters inside the
cells to form a bond with the haemoglobin to form glycosylated haemoglobin.
This hba1c gives the average blood glucose control over the past 3 months.
Hence it is necessary to check hba1c values at least twice a year.
The A1C test results could be reported as eAG or as "average glucose," which
directly correlates with A1C. eAG is a unit similar to self-monitor on the CBG
machine. A1C is reported as a percent and eAG as mg/dl .16
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eAG is not the same average glucose level as the average of values on the
meter. This is because people with diabetes more likely check blood glucose
when they are low (usually, in the morning and before meals), the average of
these readings is mostly lower than eAG.
Fasting Blood Glucose:
It is the blood glucose values which are taken in early morning with fasting for
at least 8 hours from previous night.
Oral Glucose Tolerance Test (OGTT):
It’s a test to determine how well the body metabolises glucose. Here blood
glucose values are taken in fasting. The patient is made to drink a special
glucose solution and blood glucose values are taken after 2 hours.
Result Oral Glucose Tolerance Test (OGTT)
Normal less than 140 mg/dl
Prediabetes 140 mg/dl to 199 mg/dl
Diabetes 200 mg/dl or higher16
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Random Plasma Glucose Test:
This can be done at any time of the day. When the random plasma glucose
values are more than 200mg/dl then it is diagnostic of diabetes
Prediabetes:
Prediabetes is defined as blood glucose levels which are more than normal but
not yet high to be diagnosed as diabetes.  Both impaired fasting glucose and
impaired glucose tolerance come under prediabetes. These people must be
regularly followed up for they have a high chance of developing overt diabetes
and cardiovascular complications
34
Complications:
The complications of diabetes are due to the increased blood glucose for a long
period of time. It’s the duration of diabetes which determines the incidence of
complications. The complications due to diabetes can be divided as
macrovascular and microvascular. They affect multiple organ system primarily
the kidneys, heart, eyes, brain vessels and peripheral vessels of the limbs. It
causes diabetic nephropathy, myocardial infarction, cerebrovascular accidents
and gangrene of the limbs. Moreover diabetes predisposes to hyperlipidemia
and hypertension which increases the risk of complications.
The vascular complications in diabetes mellitus are mainly due to
microangiopathy and atherosclerosis. Damage to the endothelial basement
membrane, proliferation of endothelial cells and dysfunction of the endothelial
cells are mainly responsible for the microangiopathy. Increased blood glucose
causes hardening of the vessel wall and this along with increased lipids in the
blood results in lipid deposition in atherosclerotic plaques predisposing to end
organ damage.
The pathophysiology involved in development of microvascular and
macrovascular complications in diabetes is very complex. There is no clear cut
mechanism. Increased blood glucose values for a long duration of time have
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been found to be the most important single factor causing complications.
However not all those who have increased blood glucose develop complications
and sometimes even those who have very good control of blood glucose end up
developing the complications of diabetes mellitus.
Increased sugar affects many cell types and their extracellular matrix. These
changes result in structural and functional alterations in the tissues.
The cell membranes are formed mainly by the phospholipid bilayers. Hence
alterations in lipid metabolism affect the cell membranes resulting in damage to
the cells. The oxidation of low-density lipoprotein in hyperglycaemic
individuals raises oxidant stress in the vessel wall. This attracts the monocytes
and macrophages to the vessel wall were oxidized LDL results in alterations in
cell adhesion.it also increases the release of cytokines and growth factors.
Moreover Growth factor causes multiplication of smooth muscle resulting in
increase in thickness of vessel wall. Further there is increased atherosclerotic
plaque formation and microthrombi formation in major blood vessel .the
changes in vascular permeability and endothelial cell dysfunction causes end
organ damage.
Sustained hyperglycaemia causes linking by sugar with proteins, lipids, and
nucleic acids. There is increased deposition of advanced glycation end products
in the micro blood vessels of the retina, glomerulus, and endoneurons, as well as
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the larger blood vessel walls. People who have poorly controlled diabetes
mellitus have increased formation of advanced glycation end products. These
advanced glycation end products cause change in the structural and functional
change in the cells of various tissues. AGE formation on collagen impairs
healing of damaged tissues and thus the normal homeostatic process is
deranged.  AGE-modified collagen forms in the walls of the large blood vessels
and causes vessel wall thickening and narrowness of the lumen. These
immobilize the circulating LDL, contributing to formation of atherosclerotic
plaque. The formation of AGEs causes increase in basement membrane
thickening in the retinal microvasculature and around the nerves and increase in
thickness of the mesangium in the glomerulus. The end point of all these
changes is causing narrowing of the blood vessels resulting in decreased
perfusion to the organs.
Formation of AGE has its effect at the cellular level also resulting in changes in
extracellular matrix and causing alterations in cell-to-matrix and matrix-to-
matrix interrelations. The binding of AGEs to specific cell receptors which have
been identified on the surface of smooth-muscle cells, endothelium, neural cells,
monocytes, and macrophages causes increased vascular permeability and
thrombotic complications, multiplication of smooth muscle in vasculature, and
phenotypic changes in monocytes and macrophages. This causes increased
responsiveness of monocytes and macrophages on stimulation, which results in
37
increase in the production of proinflammatory cytokines and associated growth
factors. These cytokines and growth factors contribute to the chronic
inflammation in the production of atherosclerotic lesions. They also change the
wound-healing events. More production of inflammatory mediators causes
raised tissue destruction in response to antigens such as the bacteria.
These alterations in protein and lipid metabolism, causes elevated plasma
glucose levels which is an important feature of diabetes, which provides a
common relation between the different diabetic complications. However, these
metabolic changes vary among people. For example, AGEs form in both
diabetic and non-diabetic persons, but its accumulation is more in those with
diabetes. There are significant differences in AGE formation even within the
diabetic population, and it is thought that this may explain the changes in the
incidence and progression of diabetic complications.
Management:
The main goal of treatment is to reduce the blood glucose values and keep the
values at a level similar to that of normal people and hence to prevent both
microvascular as well as macrovascular complications of diabetes mellitus.
Other goals are growth and development, normal body mass, avoiding
uncontrolled hyperglycaemia or hypoglycaemia, preventing diabetic
ketoacidosis and nonketotic acidosis, and immediately detecting and treating
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diabetic complications. Diabetics can use glucose meter to monitor the glucose
levels closely and ensure that they are within a normal range.
Obesity is a major contributor for development of diabetes. Obesity causes
insulin resistance. Hence exercise daily, diet, lifestyle modification and drugs
form a corner stage in treatment of diabetes. Type 1 diabetes patients are treated
with insulin for survival. Type 2 diabetes patients are treated with oral
hypoglycaemic agents however these patients too might require insulin for
better control.
Since the publishing of the Diabetes Control and Complications Trial in 1993
there has been great change to the drugs and the goals of therapy for treating
diabetes. This prospective randomized controlled clinical trial compared the
efficacy of intensive insulin therapy had objectives at achieving normalization
of glucose control with the presence of conventional insulin therapy on the start
and progress of complications in diabetes. The normal control group took 1 to 2
insulin injections a day whereas the intensive control cohort took 3 to 4
injections daily .During the 9-year follow-up the patients who were intensively
treated were found to have much lower complications when compared to the
other group.
In those patients who were managed intensively, the risk of retinopathy reduced
to 76% in comparison to the normal control group. The Clinical and laboratory
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signs and symptoms of nephropathy and neuropathy also reduced by 54%.
Macrovascular complications reduced significantly. These results about the
benefit of intensive therapy led the American Diabetes Association to issue its
protocol for treating type one diabetic patients that they must attain a control of
blood glucose values equal to that of the control cohort in DCCT trail.
Even for patients suffering from type 2 diabetes mellitus there is reduction in
complications in those patients in whom glucose was intensively managed
according to recent studies. In a study, maintenance of normal glycaemia
resulted in reduction by 70% the risk of microvascular and macrovascular
complications for patients, in comparison to conventional controls. Since more
than 90 percent of the patients belong to type 2 diabetes these studies have
potential to benefit millions of people worldwide.  Hence it’s imperative to
motivate diabetic patients to have strict sugar control and physicians have
intensified diabetic management nowadays.
Treatment - Oral Agents:
An array of oral agents is now available for treatment of patients with type two
diabetic mellitus. The first generation sulfonylureas are no longer in use
nowadays because of the increased side effects associated with these drugs.
Chlorpropamide is an example of first generation sulfonylureas. Second-
generation agents which are more potent, have less drug interactions, and
produce fewer side effects and hence have replaced the first generation. The
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mechanism by which sulfonylureas act is by acting on the pancreatic beta cells
and causing increase in insulin secretion. This increased insulin secretion
overcomes the resistance associated with type 2 diabetes mellitus and hence
more amount of glucose is transported inside the cells thereby decreasing the
blood glucose value. The sulfonylureas have duration of action varying from 12
to 24 hours and depending upon that they are given as single or double dosage
daily. The major adverse effect associated with sulfonylureas is hypoglycaemia.
Hence the patients who take these drugs must be educated properly to take
adequate amount of food after taking these tablets.
Repaglinide stimulates pancreatic insulin secretion. But the pharmacodynamic
properties and mechanism of action are different from sulfonylureas.
Repaglinide undergoes rapid absorption, reaches peak plasma levels in 30 to 60
minutes, and undergoes rapid metabolism. The drug is consumed along with
meals and reduces the peaks of PPBS which is common in type 2 diabetes but to
a greater degree than the sulfonylureas medications. These drugs are used for
the treatment of post prandial hyperglycaemia due to their rapid onset and short
duration of action. These drugs can also result in hypoglycaemic episodes.
Metformin are biguanides and are preferred agents for obese patients. These
drugs decrease blood glucose by decreasing the production and increasing the
utilization. These drugs also inhibit the intestinal absorption of glucose. Lactic
acidosis and megaloblastic anaemia due to vitamin b12 deficiency are the major
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adverse effects of these drugs. Biguanides increase the intestinal production of
lactate by anaerobic glycolysis. Metformin is the only oral agent that has been
demonstrated to reduce the macrovascular events in type 2 DM.
The thiazolidinedione group of drugs, which includes troglitazone,
rosiglitazone, and pioglitazone, act as agonists of nuclear receptor PPAR
gamma which regulates transcription of genes involved in glucose and lipid
metabolism. These drugs are used to reverse insulin resistance in type 2 DM.
these drugs also tend to increase HDL. The adverse effect of these drugs
includes weight gain, edema and plasma volume expansion. Therefore these
should be avoided in CHF patients.
Acarbose- complex carbohydrates are absorbed after conversion to simple
carbohydrates by alpha glucosidase. Inhibitors of this enzyme decrease
carbohydrate absorption for git. Major adverse effect is flatulence due to
fermentation of unabsorbed carbohydrates. These drugs help in restoring beta
cell function and prevent new cases of type 2 diabetes in pre diabetes
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FIG: CHART SHOWING THE DIFFERENT TREATMENTS FOR DIABETES AND ITS
EFFICACY
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Fig: Diagram showing site of action of anti-diabetic drugs
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Insulin:
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Insulin was discovered by Banting and Best in the year 1921. Glucose is the
main stimulus for the release of insulin from the beta cells of the pancreas.
Glucose stimulates GLUT-2 and inhibits ATP sensitive k+ channels. The
actions of insulin include stimulation of entry of glucose in muscle and fat,
inhibition of glycogenolysis and gluconeogenesis and increasing glycolysis and
glycogenesis. By all the above mentioned mechanisms insulin decreases the
blood glucose levels. It also inhibits lipolysis and favours deposition of
triglyceride. It caused increased synthesis of proteins and thus overall has an
anabolic action.
The human insulin is prepared by recombinant DNA technology and has rapid
absorption and shorter duration of action. Recently ultra-short acting and ultra-
long acting preparations have also been developed. All insulin preparations are
supplied at neutral pH of 7.2 to 7.4 except glargine which is supplied at pH of 4.
Hence it is important that glargine should not be mixed with any other
preparation of insulin.
All insulin preparations are given by subcutaneous route only. Only regular
insulin can be given by intra venous route. The factors which affect the
absorption of insulin include the type and site of injection, the depth of injection
and subcutaneous blood flow.
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The most common complication of an insulin therapy is hypoglycaemia. This
can be treated with intravenous glucose. Some people suffer from
hypoglycaemic unawareness. Usually when the blood glucose levels drop less
than 60mg/dl the symptoms of hypoglycaemia becomes apparent. However in
patients suffering from hypoglycaemic unawareness there is no symptoms till
blood glucose values plummets to 40mg/dl. The patient becomes unconscious
and often this condition is life threatening. Then at the site of injection it can
cause lipodystrophy. Allergic reactions and sodium and water retention have
found to occur.
The indications of insulin therapy include all cases of insulin dependent
diabetes mellitus. Among non insulin dependent diabetes mellitus insulin is
indicated when glucose levels are not controlled with oral hypoglycaemic
agents, in pregnancy and in complications like diabetic ketoacidosis and
hyperosmolar coma in in stressful conditions like surgery and infections.
The use of exogenous insulin provides a profile similar to the non-diabetic
individual, with a continuous availability of insulin available which is enhanced
by increase in availability after each meal. No single insulin preparation is
available which are able to achieve this goal with one or two injections daily.
Insulin preparation combinations are available which are taken three or more
times daily or using a subcutaneous infusion pump more approximate to the
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ideal conditions, but even in conditional regimes, blood glucose levels can
remain unstable.
Ultralente insulin also called as "peakless" insulin is the longest acting insulin.it
has a very slow action onset of action and it peaks very minimum and action is
for a longer duration. It action resembles the basal metabolic insulin which is
secreted from a normally functioning pancreas. The intermediate-acting insulin
(lente and neutral protamine Hagedorn [NPH]) have their peak action several
hours after injection. Peak activity occurs between 4 to 10 hours after injection.
Therefore a patient who is using intermediate-acting insulin in the early
morning will have peak plasma insulin levels during lunch hours. Regular
insulin is shorter acting, with its onset being around about 30 minutes through 1
hour post injection and  peaks at 2 -3 hours. Lispro insulin, a rapid acting
insulin, due to its rapid absorption, will become active about 15 minutes post
injection, and peaks at ½ to 11/2 hours. Rapid- and short-acting insulin are
usually taken just before or during meals. Thus, regular insulin when taken
before breakfast will peak at midmorning; when taken before lunch, will peak at
mid-afternoon.
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Prevention:
Daily regular exercise, healthy food habits, having an apt weight plays a major
role in preventing diabetes and the complications. These also help in reducing
the blood pressure and heart disease among type 2 diabetic patients.
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DIABETES AND THYROID
In liver, skeletal muscle and adipose tissue the thyroid hormones have different
modes of action and hence these are the main targets of action. Their action is
opposite to that of insulin and increases gluconeogenesis and glycogenolysis in
the liver.61, 62
They act by up-regulating the expression of GLUT-4 and phosphoglycerate
kinase genes, thus facilitating their action along with insulin63, 64 and improving
the disposal and utilisation of sugar in tissues.60, 65
Thyroid disease in the general
population: 6.6%
Thyroid disease in diabetes:
Overall prevalence: 10.813.4%
Hypothyroidism: 36%
Subclinical hypothyroidism: 5-
13%
Hyperthyroidism: 12%
Postpartum thyroiditis: 11%
There is a strong association between thyroid disease and type-2 diabetes, and
there are vital consequences for it on insulin sensitivity and treatment. The basis
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of this association pathophysiologically has been better described recently. The
basis is a complex interplay of major signal paths and associated genetic
susceptibility. The mechanisms which underlie this linked process are being
studied more. The explanation to this regulation is by 5' adenosine
monophosphate-activated protein kinase (AMPK) which regulates the insulin
sensitivity and also the thyroid hormone feedback.5 There are many significant
citings that have shown a more than normal prevalence of thyroid disorders in
type 2 diabetic patients, with hypothyroidism especially subclinical
hypothyroidism which is the most commonly associated with diabetes.3,4,39
The figure below shows the relation of diabetes and thyroid normally:
There are few studies that suggests genetic basis between thyroid disease and
type two diabetes (unlike type-1 diabetes) 54. Recently data have been produced
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showing association between de-iodinase 2 gene, Thr92Ala, and increased
development of type diabetes mellitus. This was strongly supported by a meta-
analysis of 11,000 people showing the place of intracellular T3 on sensitivity of
insulin.
Carbohydrate metabolism have shown many changes in hypothyroidism, signs
and symptoms of which are not conspicuous. But the insulin degradation
decreases the requirement for exogenous insulin. In presence of hypoglycaemia
in isolated hypothyroidism (clinical/subclinical) the probability of
hypopituitarism in a hypothyroid patient should be suspected. More notably,
many lipid metabolism abnormalities are associated with hypothyroidism, such
as increased triglycerides and LDL cholesterol. Coexisting dyslipidaemia in
subclinical hypothyroidism may increase and this is commonly associated type-
2 diabetes and raises the risk for cardiovascular diseases. Thyroxine
replacement if adequate will normalise the lipid abnormalities and bring it back
to normal. Diabetic kidney injury which is severe can be thought of as
hypothyroidism because both categories of patients can have swelling of body
and legs, weakness, anaemia, and gain of weight.
Poorly controlled diabetes further complicates the diagnosis of hypothyroidism
that can produce changes in thyroid function tests which can happen in absence
of thyroidal illness too. The alterations typically include a reduced T3 due to
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changes in extrathyroidal T4 to T3 conversion, a decreased level of T4 due to
decrease in protein binding, and associated low levels of TSH in blood.
The short term and long term interaction of thyroid hormones on glucose and
lipid metabolism with regulation of energy web and through its direct relation
with insulin regulation and glucose utilisation in peripheral tissues it regulates
the metabolic process in the body.
Glucose and Lipid Metabolism regulation by Thyroid hormones:
Recently published data suggest a vital role for regulation by hypothalamus  of
lipid and sugar control.22,37 Human data showed defects in counter-regulating
glucagon and the sympathetic portion of the autonomic system of nerves with
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hypothalamic versus defects in pituitary , which indicates the vital role of
hypothalamic glucose sensing system.38 AMPK is a conserved cellular energy
sensor which controls cell metabolism, and nutritional and hormonal support
maintenance in the body.39 AMPK knockout in related POMC or agouti-related
protein-expressing  neurons lead to changes in energy control. The mice which
knocked out of the gene and used for AMPKα2-regulated POMC were fat as a
consequence of reduced use of energy and feeding which was irregularised.
Their response to leptin and insulin was good but the sensing of extracellular
sugar levels was impaired. On the contrary, AMPK2α KO in AgRP nerve cells
remained thin and was showing increased sensing of melanocortin.37 The
control of metabolism by hypothalamus through AMPK been discovered in very
close times. Glucose production in peripheral tissues can be reduced by AMPK
inhibition.39AMPK  regulates in sugar utilisation through fatty acid synthesis by
the catalytic reaction regulated by acetyl coA carboxylase which is used to
convert acetyl CoA to malonyl CoA. This said reaction which is the rate
limiting step of fatty acid synthesis is controlled by AMPK phosphorylation and
this results in the formation of malonyl-CoA, and this results in elongation of
fatty acid chains which is catalysed by fatty acid synthase .40 Malonyl-CoA also
suppresses fatty acid oxidation by controlling the translocation of fatty acids
into the mitochondria, a reaction catalysed by carnitine palmitoyl transferase-1
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. Glucose control and regulated food intake can be achieved by keeping this
pathway as a target in obesity and for decreasing lipid oxidation by
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hypothalamus.41 Thyroid hormones control the above two important regulatory
steps in a direct manner.29Peripherally, AMPK is dependently stimulated by T3
in terms of dose and time.42 CPT-1 and mitochondriogenesis is stimulated by T3
and T3 mimetics though its action on CPT-1.43 This increases the probability
that direct targets of thyroid hormones include CPT-1 and AMPK, which has
recently been confirmed experimentally in animals .22 Hypothyroid animals
have been evaluated and showed a rise in concentration of AMPKα1 and role on
hypothalamus but not muscle or fat. Activity of AMPK reduced when T3 was
injected over long periods intracerebrally at a dose which does not have the
capacity of rising T3 levels in peripheral tissues. More evidence addition was
produced when AMPKα inhibition was achieved by stereotactic injection of a
negative variety of AMPK into hypothalamus’s ventromedial segment in rats
which were euthyroid. Weight loss in phenotypic variety of rats was
independent of feeding. Energy-regulating neuropeptides in the hypothalamus
had a controlled expression, but beta adrenergic stimulation of the brown fat
was characteristically raised.CPT1 was associated changes in AMPK; this
associates thyroid hormone related control with energy regulation proteins
which act peripherally such as ghrelin that makes AMPK/CPT1 regulatory
system in the hypothalamus as the main target. Energy maintenance and
hypoglycaemia’s counter regulation are controlled by the effect of ghrelin in the
body and thus shows its vitality.
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Fig: Regulation of AMPK by thyroid hormones
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Thyroid Hormones, Ghrelin and Adipokine Regulation:
Different effects of thyroid hormones have been reported on adipokine
regulation, in particular leptin. TNFα which is raised in decreased thyroid
function is showing that the major adipokines which is associated with insulin
resistance reduces the disposal of glucose and rise in fatty acids47. An increase
in IL-6is more linked to insulin resistance and is the primary marker and the
above said association is only secondary to the relation between diabetes and
hypothyroidism.47
Effects of Thyroid Hormones on Insulin Secretion and Sensitivity in
peripheral tissues:
The effect of thyroid hormones, T4 and T3, on body homeostatic energy and
metabolic regulation is explained by its action on peripheral tissues. Secretion
of insulin is influenced by thyroid hormone. Hypothyroidism caused decrease in
glucose-related beta cell insulin secretion. Gene array studies in hypothyroid
patient’s skeletal muscle have shown a classical effect on sugar transporter
expression by down regulating the GLUT5 in hypothyroidism. On the contrary,
expression of GLUT4 is not changed, but model animals showed altered
translocation of GLUT4 to the cell membrane and negative alteration of enzyme
based degradation of intracellular sugar in decreased thyroid function’s
presence20. The oxidation of glucose and synthesis of glycogen are reduced in
decreased thyroid function. The sensitivity of insulin is improved parallely with
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rising thyroid hormone concentrations. This is dependent on production of T3
within the cells as polymorphisms of de-iodinase with reduced generation of T3
have a close association with resistance of insulin in diabetic patients.
Thyroid Hormone and Insulin Resistance:
A positive association between insulin resistance and thyroxine is not only
diabetic patients but also in people with normal sugar tolerance. Insulin
resistance indices as evaluated by the homeostatic model assessment (HOMA,
which judges before meal and post meal resistance of insulin) are related to
normally functioning thyroid subjects, where HOMA is associated with an
increase in thyroid concentrations normally.
The interaction between thyroid status and metabolic control shows the
requirement for keen monitoring of thyroid function in type 2 diabetes mellitus
patients. As proved through studies that thyroid dysfunction prevalence in
T2DM is similar to T1DM, it is necessary to put forth new recommendations for
frequently investigation, on yearly or twice yearly basis, in groups which are of
greater risk like patients over 50 or 55 years, especially in presence of clinical,
increased titres of antibody or lipid abnormalities. So it is necessary to suggest
that an initial testing of TSH and TPO antibody that helps to analyse the
development of hypothyroidism in patients with diabetes mellitus.
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Indications for Treatment of Persistent Subclinical Hypothyroidism7
Postmenopausal osteoporosis
Rheumatic valvular disease with left atrial enlargement or atrial
fibrillation Recent-onset atrial fibrillation or recurrent cardiac arrhythmias
Congestive heart failure
Angina pectoris
Infertility or menstrual disorders
Nonspecific symptoms such as fatigue, nervousness, depression, or
gastrointestinal disorders,
especially in patients older than 60 years of age (consider therapeutic trial)
Diet for Diabetes with Hypothyroidism:
A food combination for diabetes with hypothyroidism requires specific details.
Intake of certain foods with hypothyroidism or diabetes causes symptoms to
exacerbate. Knowledge of what to eat, and when, help in managing blood
glucose levels and thyroid hormone levels. Hypothyroidism commonly causes
weight to increase, which further deteriorates the blood sugar control. A diet for
both illnesses should certainly address weight, food reactions, and blood sugar
levels (glycaemic index).
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What to Eat:
A healthy diet which is full of nutrient-dense foods and which has less of
carbohydrates is the most important combination for diabetes and
hypothyroidism. Vegetables and lean protein must consist of in the bulk of the
food. Fish, chicken breast, and lean beef are useful to be included in the diet.
Pork and turkey breast are accepted as forms of lean protein. Intake of eggs,
cheese, and yoghurt are important and not contraindicated. Vegetarians should
replace lean meat with beans and nuts as their protein source. There should
moderation while eating fruits because of their different effects on blood sugar
levels. Fruits which have lower glucose spikes should be taken. Berries are
useful. Drinking lots of water helps a lot.
When to Eat:
When to eat is very critical and is as important as what to eat in diabetes with
hypothyroidism. Skipping breakfast is harmful as it is the precursor of
metabolism. We should take smaller meals which are spread through the entire
day and not rely on two or three large meals. The biggest meals should be early,
and supper should be light. Healthy foods should be used as snacks when
hunger sets in. Dinner should be the last meal. Lean protein snacks should be
taken as snacks.
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Foods to Avoid:
High-carbohydrate foods should not be taken, and when consumed, the portion
sizes should be in the right manner. Cruciferous vegetables are an important
alternative (such as broccoli) in moderation as they cause interference with
thyroid gland functioning. Soy also alters the thyroid gland function and
prevents the efficacy of thyroid replacement medicines. There should be fewer
intakes of saturated fats, like fatty meats, and they should be replaced with
healthy fats, such as omega3 fatty acids, which are associated with foods like
fish and flax. Soda and other sugary drinks should be avoided from diet. Food
allergy test should be done to show any specific foods to avoid. Food allergies
are sometimes associated with other autoimmune diseases like hypothyroidism
due to similar etiologies.
Weight Loss:
Maintenance of a healthy weight for better blood sugar control plays a vital
role, but this becomes more difficult in conjunction with hypothyroidism.
Losing weight becomes next to impossible. Metabolism will be slower and the
body cannot function as it should normally. Exercise should be put into the
daily schedule of the patient for better control of weight and sugar levels. The
ADA recommends that at least 30 minutes a day should be spent in exercise.
Sleep also plays a vital role. When sleep is not enough the body will have a
cortisol imbalance, which results in feeling hungry even after consumption of
61
food. Decreased sleep will also affect the body’s ability for carbohydrate break
down, and this result in a raise in blood sugar. Sleep deprivation should be
prevented.
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III. AIMS AND OBJECTIVES
The main objectives of the study are as follows:
1. To study the prevalence of Hypothyroidism (Clinical/Subclinical) in
Diabetic patients
2. To study the correlation of HbA1c levels with TSH levels
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IV. MATERIALS AND METHODS
PLACE OF STUDY
Stanley Medical College and Hospital, Chennai:
Department of General Medicine, Endocrinology OPD, Medical wards
SAMPLE SIZE: 50
DURATION
February 2014 - September 2014.
STUDY DESIGN
Prospective Observational Study
ETHICAL COMMITTEE APPROVAL
Ethical committee approval was obtained for the study
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PATIENT SELECTION
Inclusion Criteria:
1. Any patient coming with history of type 2 Diabetes Mellitus of more
than 3 years duration with or without Hypothyroidism.
2. Any patient on treatment for Hypothyroidism with history of type 2
Diabetes.
Exclusion Criteria:
1. Patients with type 2 Diabetes Mellitus for less than 3 years duration.
2. Patients in Hyperglycaemic emergencies.
3. Patients with pervious history of Thyroid surgery.
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METHODOLOGY
Patients coming with history of type 2 diabetes mellitus with or without history
hypothyroidism of more than 3 years duration or patients on treatment for
hypothyroidism with history of diabetes mellitus presenting to OPDs or
admitted in wards from February 2014 to September 2014 are included in the
study. Patients are subjected to symptom analysis, clinical examination, blood
investigations including HBA1C and TSH levels. The newly diagnosed patients
of hypothyroidism in diabetes were treated with thyroxine for three months and
followed up with TSH and HBa1c levels.  The final analysis will be made at the
end of the study to achieve the aforementioned goals.
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CONSENT
The study group thus identified by the above criteria (inclusion and exclusion
criteria) was first instructed about the nature of the study. Willing participants
were taken up for this study after getting a written / informed consent from
these patients or their relatives in the local vernacular language.
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STUDY SUBJECTS
All   the  patients  who  fulfilled  the inclusion  criteria  above  30 years of  age
and  both  genders  were  included  in  this  study. The  included  patients were
subjected to detailed history taking, complete physical examination  and  the
relevant  laboratory  investigations  as per a proforma, exclusively  designed for
the  study.
The details of the thyroid problem and diabetes mellitus were obtained from the
patients and attenders and scrutinising their old records closely.
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V. RESULTS AND DISCUSSION
GROUP DISTRIBUTION
Treatment
Groups
Name of
Group Study
Number
of
Subjects
Group A Euthyroid To assess the prevalence of
hypothyroidismin diabetes mellitus
45
Group B Hypothyroid 5
STATISTICS
Descriptive statistics was done for all data and suitable statistical tests of
comparison were done. Continuous variables were analysed with the Unpaired t
test and categorical variables were analysed with the Chi-Square Test and
Fisher Exact Test. Statistical significance was taken as P < 0.05. The data was
analysed using EpiInfo software (7.1.0.6 version; Center for disease control,
USA) and Microsoft Excel 2010.
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SAMPLE SIZE CALCULATION
Sample size was determined on the basis of a pilot study in which the
prevalence of hypothyroidism in diabetes mellitus was measured at 15%.  We
calculated a minimum sample size of 48 patients was required in each group,
assuming a type 1 error (two-tailed) of 0.05 and a margin of error of 10%.
Therefore, the final sample selected was n= 50.
n = t² x p(1-p)
m²
Description:
n = required sample size
t = confidence level at 95% (standard value of 1.96)
p = estimated prevalence of malnutrition in the project area (15%)
m = margin of error at 10% (standard value of 0.05)
n = (1.96)² x 0.15(1 - 0.15)
(0.01)²
n = 3.8146 x 0.1275
=
0.0001
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AGE DISTRIBUTION
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Discussion:
Age
Distribution All % Euthyroid % Hypothyroid %
41 to 50 8 16 8 17.77778 0 0
51 to 60 36 72 33 73.33333 3 60
61 to 70 6 12 4 8.888889 2 40
Total 50 100 45 100 5 100
Age Distribution Euthyroid Hypothyroid
N 45 5
Mean 55.27 59.00
SD 4.43 6.75
P value
Unpaired t test 0.2877207
By conventional criteria the association between the study groups and age is
considered to be not statistically significant since p > 0.05.
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GENDER
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Discussion:
Gender
Distribution All % Euthyroid % Hypothyroid %
Male 16 32 16 35.56 0 0
Female 34 68 29 64.44 5 100
Total 50 100 45 100 5 100
Chi-square
statistic 2.61
Degrees of
freedom 1
P value
Chi squared
Test without
Yates
Correction
0.106
By conventional criteria the association between the study groups and gender is
considered to be not statistically significant since p > 0.05.
Since age and gender is not statistically significant, it means that there is no
difference between the groups. In other words the groups contain subjects with
the same basic demographic characteristics.
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DURATION OF DIABETES
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Discussion:
Duration of
DM All % Euthyroid % Hypothyroid %
≤ 5 years 23 46 20 44.44 3 60
6 to 10
years 24 48 23 51.11 1 20
> 10 years 3 6 2 4.44 1 20
Total 50 100 45 100 5 100
Duration of DM Euthyroid Hypothyroid
N 45 5
Mean 6.00 7.60
SD 2.08 3.71
P value
Unpaired t test 0.03940563*
By conventional criteria the association between duration of diabetes and
hypothyroidism is considered to be statistically significant since p < 0.05.
Statistical Significance:
This indicates that there is a true difference among the study groups and the
difference is significant.
In simple terms, while assessing the prevalence of hypothyroidism in in diabetes
mellitus, the average duration of diabetes mellitus is 6 years in euthyroid
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patients compared with 7.6 years in hypothyroid patients with a p-value of
0.03940563 according to Chi-Squared test.
Clinical Significance:
The duration of diabetes mellitus is meaningfully less (26.66%) in euthyroid
compared to hypothyroid patients by a difference of 1 year and 7 months. Also
the incidence of hypothyroid state in diabetic patients is much more in the first
five years of diabetes mellitus (60%).  This difference is true and significant and
has not occurred by chance.
Conclusion:
We conclude that there is an increased frequency of hypothyroidism early in
duration of diabetes mellitus.  This also proves that diabetes mellitus patients
are at risk of developing hypothyroidism as a complication more in the first five
years in our study.
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FASTING BLOOD SUGAR
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Discussion:
Fasting Blood
Sugar All % Euthyroid % Hypothyroid %
≤ 100 mg/dl 50 100 5 11.11 1 20
101 to 110
mg/dl 0 0 16 35.56 0 0
> 110 mg/dl
years 0 0 24 53.33 4 80
Total 50 100 45 100 5 100
Fasting Blood Sugar Euthyroid Hypothyroid
N 45 5
Mean 111.98 119.00
SD 8.91 13.08
P value
Unpaired t test 0.008211*
By conventional criteria the association between fasting blood sugar and
hypothyroidism is considered to be statistically significant since p < 0.05.
Statistical Significance:
This indicates that there is a true difference among the study groups and the
difference is significant.
In simple terms, while assessing the prevalence of hypothyroidism in diabetes
mellitus, the average fasting blood sugar is 111.98 mg/dl in euthyroid patients
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compared with 119 mg/dl in hypothyroid patients with a p-value of 0.008211
according to Chi-Squared test.
Clinical Significance:
The average fasting blood sugar is meaningfully less (6.27%) in euthyroid
patients compared to hypothyroid patients by a difference of 7.02 mg/dl. This
difference is true and significant and has not occurred by chance.
Conclusion:
We conclude that there is an increased frequency of higher fasting blood
glucose in hypothyroid patients.  This study shows that the hypothyroid
condition will causes overall higher average fasting blood glucose than normal.
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Discussion:
Post Prandial
Blood Sugar All % Euthyroid % Hypothyroid %
≤ 150 mg/dl 17 34 16 35.56 1 20
151 to 200
mg/dl 30 60 27 60.00 3 60
> 200 mg/dl
years 3 6 2 4.44 1 20
Total 50 100 45 100 5 100
Post Prandial Blood
Sugar Euthyroid Hypothyroid
N 45 5
Mean 159.40 172.60
SD 20.64 26.62
P value
Unpaired t test 0.3366892
By conventional criteria the association between the study groups and post
prandial is considered to be not statistically significant since p > 0.05.
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HbA1c (Fasting Value)
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Discussion:
HbA1c(FV) All % Euthyroid % Hypothyroid %
≤ 6 % 0 0 0 0.00 0 0
6.1 to 8 % 43 86 40 88.89 3 60
> 8% 7 14 5 11.11 2 40
Total 50 100 45 100 5 100
HbA1c(FV) Euthyroid Hypothyroid
N 45 5
Mean 7.54 8.76
SD 0.49 0.59
P value
Unpaired t test 0.0022491*
By conventional criteria the association between HBA1c-Fasting value and
hypothyroidism is considered to be statistically significant since p < 0.05.
Statistical Significance:
This indicates that there is a true difference among the study groups and the
difference is significant.
In simple terms, while assessing the prevalence of hypothyroidism in diabetes
mellitus, the average HBA1c-Fasting value is 7.54% in euthyroid patients
compared with 8.76% in hypothyroid patients with a p-value of 0.0022491
according to Unpaired t- test.
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Clinical Significance:
The average HBA1c-Fasting value is meaningfully less (2.89%) in euthyroid
patients compared to hypothyroid patients by a difference of 1.22%. This
difference is true and significant and has not occurred by chance.
Conclusion:
We conclude that there is an increased frequency of higher HBA1c-Fasting
value in hypothyroid patients.  This study shows that the hypothyroid condition
will cause an overall higher average HBA1c-Fasting value than normal.
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Hba1c (After Thyroxine)
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Discussion:
Hba1c(After
Thyroxine) All % Euthyroid % Hypothyroid %
≤ 6 % 1 2 1 2.22 0 0
6.1 to 8 % 47 94 42 93.33 5 100
> 8% 2 4 2 4.44 0 0
Total 50 100 45 100 5 100
Hba1c(After Thyroxine) Euthyroid Hypothyroid
N 45 5
Mean 7.18 7.24
SD 0.42 0.62
P value
Unpaired t test 0.033053*
By conventional criteria the association between HBA1c-After Thyroxine value
and hypothyroidism is considered to be statistically significant since p < 0.05.
Statistical Significance:
This indicates that there is a true difference among the study groups and the
difference is significant.
In simple terms, while assessing the prevalence of hypothyroidism in diabetes
mellitus, the average HBA1c-After Thyroxine value is 7.18% in euthyroid
patients compared with 7.24% in hypothyroid patients with a p-value of
0.033053 according to Unpaired t- test.
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Clinical Significance:
The average HBA1c- After Thyroxine value is meaningfully less (0.89%) in
euthyroid patients compared to hypothyroid patients by a difference of 0.06%.
This difference is true and significant and has not occurred by chance.
Conclusion:
We conclude that there is a decreased frequency of higher HBA1c- After
Thyroxine value in hypothyroid patients compared to HBA1c-Fasting values.
This study shows that the corrected hypothyroid condition will cause a lower
average HBA1c- After Thyroxine value very near to normal.
HBA1c Levels Mean (Euthyroid) Mean (Hypothyroid)
HBA1c Fasting Value 7.54 mg/dl 8.76 mg/dl
HBA1c After Thyroxine
Value 7.18 mg/dl 7.24mg/dl
P value
Paired t-test 0.0000* 0.0138*
Pearson Correlation 0.783429338 0.895299319
By conventional criteria the association between HBA1c-Fasing and After
Thyroxine values are considered to be statistically significant since p < 0.05.
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The average HBA1c- After Thyroxine value is meaningfully less (21%) in
hypothyroid patients compared to HBA1c Fasting values by a difference of
1.52% with a p-value of 0.0138 according to Paired t-test.. This difference is
true and significant and has not occurred by chance.
There is a strong positive correlation between HBA1c-Fasing and After
Thyroxine values among Hypothyroids in diabetes mellitus subjects in our
study. This is indicated by the Pearson's R Correlation value of 0.895299319.
The increase inHBA1c levels among diabetics correlates positively, directly and
strongly with the increase in hypothyroid status this means as the hypothyroid
status increases as the HBA1c values increase.
.
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Discussion:
TSH(FV) All % Euthyroid % Hypothyroid %
≤ 4 mu/l 1 2 1 2.22 0 0
4.1 to 6
mu/l 40 80 39 86.67 1 20
> 6 mu/l 9 18 5 11.11 4 80
Total 50 100 45 100 5 100
TSH(FV) Euthyroid Hypothyroid
N 45 5
Mean 5.58 6.94
SD 0.64 0.86
P value
Unpaired t test 0.0222323*
By conventional criteria the association between TSH-Fasting value and
hypothyroidism is considered to be statistically significant since p < 0.05.
Statistical Significance:
This indicates that there is a true difference among the study groups and the
difference is significant.
In simple terms, while assessing the prevalence of hypothyroidism in diabetes
mellitus, the average TSH-Fasting value is 5.58 mu/l in euthyroid patients
compared with 6.94 mu/l in hypothyroid patients with a p-value of 0.0222323
according to Unpaired t- test.
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Clinical Significance:
The average HBA1c-Fasting value is meaningfully less (24.42%) in euthyroid
patients compared to hypothyroid patients by a difference of 1.36 mu/l. This
difference is true and significant and has not occurred by chance.
Conclusion:
We conclude that there is an increased frequency of higher TSH-Fasting value
in hypothyroid patients.  This study shows that the hypothyroid condition will
cause an overall higher average TSH-Fasting value than normal.
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TSH (After Thyroxine)
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Discussion:
TSH(After
Thyroxine) All % Euthyroid % Hypothyroid %
≤ 4 mu/l 0 0 0 0.00 0 0
4.1 to 6
mu/l 45 90 44 97.78 1 20
> 6 mu/l 5 10 1 2.22 4 80
Total 50 100 45 100 5 100
TSH(After Thyroxine) Euthyroid Hypothyroid
N 45 5
Mean 5.42 5.74
SD 0.34 0.76
P value
Unpaired t test 0.0173477*
By conventional criteria the association between TSH-After Thyroxine value
and hypothyroidism is considered to be statistically significant since p < 0.05.
Statistical Significance:
This indicates that there is a true difference among the study groups and the
difference is significant.
In simple terms, while assessing the prevalence of hypothyroidism in diabetes
mellitus, the average TSH-After Thyroxine value is 5.42 mu/l in euthyroid
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patients compared with 5.74 mu/l in hypothyroid patients with a p-value of
0.0173477according to Unpaired t- test.
Clinical Significance:
The average TSH- After Thyroxine value is meaningfully less (5.86%) in
euthyroid patients compared to hypothyroid patients by a difference of 0.32
mu/l This difference is true and significant and has not occurred by chance.
Conclusion:
We conclude that there is a decreased frequency of higher TSH- After
Thyroxine value in hypothyroid patients compared to TSH-Fasting values.  This
study shows that the corrected hypothyroid condition will cause a lower average
TSH- After Thyroxine value very near to normal.
TSH Levels Mean (Euthyroid) Mean (Hypothyroid)
HBA1c Fasting Value 5.58 mu/l 6.94 mu/l
HBA1c After Thyroxine
Value 5.42 mu/l 5.74 mu/l
P value
Paired t-test 0.03762* 0.01161*
Pearson Correlation 0.129498659 0.969915853
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By conventional criteria the association between HBA1c-Fasing and After
Thyroxine values are considered to be statistically significant since p < 0.05.
The average TSH- After Thyroxine value is meaningfully less (20.9%) in
hypothyroid patients compared to TSH Fasting values by a difference of 1.2
mu/l with a p-value of 0.01161 according to Paired t-test.. This difference is true
and significant and has not occurred by chance.
There is a strong positive correlation betweenTSH-Fasting and After Thyroxine
values among Hypothyroids in diabetes mellitus subjects in our study. This is
indicated by the Pearson's R Correlation value of 0.969915853. The increase in
TSH levels among diabetics correlates positively, directly and strongly with the
increase in hypothyroid status this means as the hypothyroid status increases as
the TSH values increase.
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VI. CITATIONS
1. Leu wei et al at capital medical university in Beijing’s Tongren hospital  did
a study to find out the effect of subclinical hypothyroidism on diabetes
mellitus and on glucose metabolism where they followed up 1170 cases of
type 2 diabetes mellitus with subclinical hypothyroidism. They found that in
their study population the hypothyroid patients with subclinical
hypothyroidism had significant abnormalities in glucose metabolism like
control of fbg,ppbg,hba1c and they found significant positive correlation
(p<.001) between the parameters.
2. Zeleja Velija-Asimi et al at University Clinical Centre, Sarajevo performed a
trial to study the effects of subclinical hypothyroidism on effects of
subclinical hypothyroidism on metabolic control and hyperinsulinemia. The
study included 53 patients of which 12 patients had type 2 diabetes mellitus.
They followed up the patients for 6 months after administering L-thyroxine.
They found a better control of FBS, PPBS and HbA1C and fasting lipid
profile. They found a positive correlation(r=0.41) between HBA1C and TSH
and positive correlation between HBA1C and insulin(r=0.35).Thus they
concluded that normalised TSH levels will result in decreased levels of
fasting insulin, FBS, PPBS and HBA1C.
3. Edina Bilic-Komarica et al conducted a study to understand the effects of
treatment of L-thyroxine on glucose regulation in patients with subclinical
hypothyroidism. The study group consisted of 100 patients out of which 38
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patients were diabetic. The patients were followed up after 6 months of L-
thyroxine (25-50mcg) and physical activity and tests performed were T3, T4,
TSH, HBA1C, CRP, and insulin and lipid levels. After 6 months testing
showed significantly reduced FBS,PPBS,HBA1c(r=0.46),fasting insulin and
lipids thus concluding that normalising TSH levels with thyroxine treatment
will control blood sugar better than other groups.
4. CEJ Udiong et al studied the glycaemic indices and thyroid hormone in type
1 and type Diabetes Mellitus.18 type 1 and 143 type 2 diabetic patients were
enrolled in the study and FPG, HBA1c and c peptide levels were assayed.
Correlation of HBA1c and TSH had significant correlation (r=0.211, p<0.1)
in type 2 diabetes while in type 1 diabetes there was negative association.
5. Zhao jin Liang et al studied the relationship between glycosylated
haemoglobin and thyroid hormones in type 2 diabetes patients and found a
positive correlation between HBA1c and TSH levels, T3 and T4 levels and
correlation was found to be statistically significant (p<.01).So conclusion
was made that thyroid hormones improve with appropriate blood sugar
control in type 2 diabetes mellitus patients.
6. SAP Chubb et al studied the prevalence and progression of subclinical
hypothyroidism in women with type 2 diabetes. They did a cross sectional
and longitudinal observational study on 420 randomly assigned females.
TSH, free T4 and TPO antibodies, HBa1c and, glucose and lipid profile was
measured. The prevalence of hypothyroidism was found to be 8.6 %( after
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excluding the already hypothyroid patients. So they concluded that
subclinical hypothyroidism was an incidental finding in type 2 diabetes and
routine screening was questionable.
7. Abdal Rahman M. Radaideh et al from Jordan studied the prevalence of
thyroid dysfunction and autoimmunity in type 2 diabetic patients. A group of
908 patients were investigated and underwent thyroid function tests. As a
result of this study 6.6% of the patients were diagnosed newly with
hypothyroidism of which 4.1 % (p<0.5) had subclinical hypothyroidism.
Anti tpo was positive in 8.3%.Thus the study suggested that diabetic patients
should be screened for hypothyroidism.
8. Mohammed Afdhami-Ardekani et al studied effect of metabolic response in
type 2 diabetes patients. They used thyroid function tests, lipid profile and
glycated haemoglobin in type 2 diabetic patients and cross sectional study
was carried out on1200 patients. Study concluded that higher proportion of
type 2 diabetes patients have thyroid dysfunction and more of metabolic
disturbances (p<0.02).
9. Avraham Ishay et al studied the prevalence of subclinical hypothyroidism in
women with type 2 diabetes mellitus.410 women with type 2 diabetes and
125 non diabetic patients were included in the study found in their study that
routine screening is not warranted(p=0.3,p=0.75)as the prevalence of
hypothyroidism in both study and control groups were similar.
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10.E. Maratou et al performed to correlate the study of insulin resistance and
insulin related glucose transport in patients with clinical and subclinical
hypothyroidism.3 groups of patients one euthyroid, one hypothyroid and one
sub clinical hypothyroid were studied by assessing the metabolism of insulin
both in vivo and in vitro. The results showed that insulin resistance was more
hypothyroid and subclinical hypothyrosis patients and insulin stimulated
glucose transport via GLUT4 was impaired. So these findings also suggested
increased incidence of insulin resistance disorders in thyroid patients.
11.V Uppal et al studied the existence of thyroid dysfunction in type 2 diabetic
patients in people of north India and correlate thyroid hormones with serum
insulin and HBa1c.A case control study was carried out on117 adults of
same age group. The study showed significant relation between HBa1c and
thyroid hormones but no relation between thyroid hormones and insulin
levels.
12.HA Begum et al studied the co-occurrence of type 2 diabetes and thyroid
metabolic disorders.50 type 2 diabetes patients were studied and T3, T4,
TSH, anti tpo were studied in diabetic patients and correlated with HBa1c,
FPG, and PPBG. The study showed significant low free T3 (free T3
syndrome) in diabetic patients (p=0.00) in which there was no thyroid
autoimmunity.
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VII. CONCLUSION
Diabetes Mellitus and hypothyroidism are very closely related to each other and
both are associated with several metabolic abnormalities. There are many
common features in both these endocrine disorders.
The normalization of TSH levels leads to a reduction in postprandial glucose
levels, CRP, HbA1c and lipids. This indicates a significant effect of treatment
with L-thyroxine on glycemic control in patients with subclinical
hypothyroidism.
Determination of TSH is accurate, accessible, safe and inexpensive test to
diagnose subclinical hypothyroidism. Determining the level of TSH can be used
to define the risk of the occurrence of various complications (osteoporosis,
cardiovascular disease, depression) for different intervals between TSH.
Subclinical hypothyroidism is quite hard to diagnose. In practice this is often
overlooked. Adequate diagnosis requires conducting extensive laboratory tests
other than routine as the TSH test. Monitoring of body temperature and careful
monitoring of clinical signs, then well taken case history helps to faster and
easier detection of this disease in medical practice.
My study revealed a strong correlation between duration of diabetes and
hypothyroidism, FBS values and hypothyroidism.Hba1c before and after
thyroxine, TSH before and after thyroxine also revealed a strong
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coreelation(p<.05).The main part of my study which revealed a strong
correlation between Hba1c and TSH levels.
As per the previous studies (as in citations) and my study, I can conclude that
there was high prevalence of hypothyroidism in diabetes mellitus and there was
correlation between Hba1c and TSH levels.
More studies with similar indices have to be performed to confirm the study
results. I can also conclude that doing a TSH levels in patients of diabetes
mellitus is warranted.
BIBLIOGRAPHY
1. Centers for Disease Control and Prevention (CDC). (2003) Prevalence of diabetes and
impaired fasting glucose in adults – United States, 1999–2000. MMWR Morbidity and
Mortality Weekly Report, 52, 833–837.
2. Wild, S., Roglic, G., Green, A. et al. (2004) Global prevalence of diabetes. Diabetes Care, 27,
1047–1053.
3. Hollowell, J.G., Staehling, N.W., Flanders, W.D. et al. (2002) Serum TSH, T(4), and thyroid
antibodies in the United States population (1988 to 1994): National Health and Nutrition
Examination Survey (NHANES III). Journal of Clinical Endocrinology andMetabolism, 87,
489–499.
4. Canaris, G.J., Manowitz, N.R., Mayor, G. et al. (2000) The Colorado thyroid disease
prevalence study. Archives of Internal Medicine, 160, 526–534.
5. Vanderpump, M.A., Tunbridge, W.M., French, J.M. et al. (1995) The incidence of thyroid
disease in the community: a twenty-year follow-up of the Whickham Survey. Clinical
Endocrinology, 43, 55–68.
6. Perros, P., McCrimmon, R.J., Shaw, G. et al. (1995) Frequency of thyroid dysfunction in
diabetic patients: value of annual screening. Diabetic Medicine, 12, 622–627.
7. Kadiyala, R., Peter, R. & Okosieme, O.E. (2010) Thyroid dysfunction in patients with diabetes:
clinical implications and screening strategies. International Journal of Clinical Practice, 64,
1130–1139.
8. Barker, J.M., Yu, J., Yu, L. et al. (2003) Autoantibody ''subspecificity'' in type 1
diabetes. Diabetes Care, 28, 850–855.
9. Kordonouri, O., Maguire, A.M., Knip, M. et al. (2009) Other complications and associated
conditions with diabetes in children and adolescents. Pediatric Diabetes, 10, 204–210.
10. Holl, R.W., Boehm, B., Loos, U. et al. (1999) Thyroid autoimmunity in children and
adolescents with type 1 diabetes mellitus. HormoneResearch in Pediatrics, 52, 113–118.
11. Huber, A., Menconi, F., Corathers, S. et al. (2008) Joint genetic susceptibility to type 1
diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocrine Reviews,
29, 697–725.
12. Villano, M.J., Huber, A.K., Greenberg, D.A. et al. (2009) Autoimmune thyroiditis and diabetes:
dissecting the joint genetic susceptibility in a large cohort of multiplex families. Journal of
ClinicalEndocrinology and Metabolism, 94, 1458–1466.
13. Tomer, Y. & Menconi, F. (2009) Type 1 diabetes and autoimmune thyroiditis: the genetic
connection. Thyroid, 19, 99–102.
14. Hewagama, A. & Richardson, B. (2009) The genetics and epigenetics of autoimmune
diseases. Journal of Autoimmunity, 33, 3–11.
15. Menconi, F., Osman, R., Monti, M.C. et al. (2010) Shared molecular amino acid signature in
the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and
thyroiditis. Proceedingsof the National Academy of Sciences of the United States ofAmerica,
107, 16899–16903.
16. Pearce, S.H. & Merriman, T.R. (2009) Genetics of type 1 diabetes and autoimmune thyroid
disease. Endocrinology and MetabolismClinics of North America, 38, 289–301.
17. Howson, J.M., Dunger, D.B., Nutland, S. et al. (2007) A type 1 diabetes subgroup with a
female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a
strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene. Diabetologia,
50, 741–746.
18. Abbas, A.K., Lohr, J. & Knoechel, B. (2007) Balancing autoaggressive and protective T cell
responses. Journal of Autoimmunity, 28, 59–61.
19. Dora, J.M., Machado, W.E., Rheinheimer, J. et al. (2010) Association of the type 2 deiodinase
Thr92Ala polymorphism with type 2 diabetes: case–control study and meta-
analysis. European Journal ofEndocrinology, 163, 427–434.
20. Peppa, M., Koliaki, C., Nikolopoulos, P. et al. (2010) Skeletal muscle insulin resistance in
endocrine disease.Journal of Biomedicineand Biotechnology, 2010, 527850.
21. Dhillo, W.S. (2007) Appetite regulation: an overview. Thyroid, 17, 433–445.
22. Ló pez, M., Varela, L., Vázquez, M.J. et al. (2010) Hypothalamic AMPK and fatty acid
metabolism mediate thyroid regulation of energy balance. Nature Medicine, 16, 1001–1008.
23. Hollenberg, A.N. (2008) The role of the thyrotropin-releasing hormone (TRH) neuron as a
metabolic sensor. Thyroid, 18, 131–139.
24. Ghamari-Langroudi, M., Vella, K.R., Srisai, D. et al. (2010) Regulation of thyrotropin-releasing
hormone-expressing neurons in paraventricular nucleus of the hypothalamus by signals of
adiposity. Molecular Endocrinology, 24, 2366–2381.
25. Decherf, S., Seugnet, I., Kouidhi, S. et al. (2010) Thyroid hormone exerts negative feedback
on hypothalamic type 4 melanocortin receptor expression. Proceedings of the National
Academy of Sciencesof the United States of America, 107, 4471–4476.
26. Ishii, S., Kamegai, J., Tamura, H. et al. (2003) Hypothalamic neuropeptide Y/Y1 receptor
pathway activated by a reduction in circulating leptin, but not by an increase in circulating
ghrelin, contributes to hyperphagia associated with triiodothyronineinduced
thyrotoxicosis. Neuroendocrinology, 78, 321–330.
27. Ishii, S., Kamegai, J., Tamura, H. et al. (2008) Triiodothyronine (T3) stimulates food intake via
enhanced hypothalamic AMP-activated kinase activity. Regulatory Peptides, 151, 164–169.
28. Coppola, A., Liu, Z.W., Andrews, Z.B. et al. (2007) A central thermogenic-like mechanism in
feeding regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metabolism, 5,
21–33.
29. Klieverik, L.P., Coomans, C.P., Endert, E. et al. (2009) Thyroid hormone effects on whole-
body energy homeostasis and tissuespecific fatty acid uptake in vivo. Endocrinology, 150,
5639–5648.
30. Lönn, L., Stenlöf, K., Ottosson, M. et al. (1998) Body weight and body composition changes
after treatment of hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 83,
4269–4273.
31. Silva, J.E. (2006) Thermogenic mechanisms and their hormonal regulation. Physiological
Reviews, 86, 435–464.
32. Gambert, S. & Ricquier, D. (2007) Mitochondrial thermogenesis and obesity. Current Opinion
in Clinical Nutrition and MetabolicCare, 10, 664–670.
33. Sell, H., Berger, J.P., Samson, P. et al. (2004) Peroxisome proliferator-activated receptor
gamma agonism increases the capacity for sympathetically mediated thermogenesis in lean
and ob/ob mice. Endocrinology, 145, 3925–3934.
34. Lanni, A., Moreno, M., Lombardi, A. et al. (2003) Thyroid hormone and uncoupling
proteins. FEBS Letters, 543, 5–10.
35. Dardeno, T.A., Chou, S.H., Moon, H.S. et al. (2010) Leptin in human physiology and
therapeutics. Frontiers in Neuroendocrinology, 31, 377–393.
36. Farooqi, I.S., Keogh, J.M., Yeo, G.S. et al. (2003) Clinical spectrum of obesity and mutations
in the melanocortin 4 receptor gene. NewEngland Journal of Medicine, 348, 1085–1095.
37. Claret, M., Smith, M.A., Batterham, R.L. et al. (2007) AMPK is essential for energy
homeostasis regulation and glucose sensing by POMC and AgRP neurons. Journal of Clinical
Investigation, 117, 2325–2336.
38. Schöfl, C., Schleth, A., Berger, D. et al. (2002) Sympathoadrenal ounterregulation in patients
with hypothalamic craniopharyngioma.
39. Journal of Clinical Endocrinology and Metabolism, 87, 624–629.
40. Yang, C.S., Lam, C.K., Chari, M. et al. (2010) Hypothalamic AMPactivated protein kinase
regulates glucose production. Diabetes, 59, 2435–2443.
41. Wolfgang, M.J. & Lane, M.D. (2006) The role of hypothalamic malonyl-CoA in energy
homeostasis. Journal of Biological Chemistry, 281, 37265–37269.
42. Pocai, A., Lam, T.K., Obici, S. et al. (2006) Restoration of hypothalamic lipid sensing
normalizes energy and glucose homeostasis in overfed rats. Journal of Clinical Investigation,
116, 1081–1091.
43. Yamauchi, M., Kambe, F., Cao, X. et al. (2008) Thyroid hormone activates adenosine 5'-
monophosphate-activated protein kinase via intracellular calcium mobilization and activation
of calcium/calmodulin-dependent protein kinase kinase-beta. Molecular Endocrinology, 22,
893–903.
44. Uldry, M., Yang, W., St-Pierre, J. et al. (2006) Complementary action of the PGC-1
coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metabolism, 3,
333–341.
45. Gjedde, S., Vestergaard, E.T., Gormsen, L.C. et al. (2008) Serum ghrelin levels are increased
in hypothyroid patients and become normalized by L-thyroxine treatment. Journal of Clinical
Endocrinologyand Metabolism, 93, 2277–2280.
46. Granata, R., Baragli, A., Settanni, F. et al. (2010) Unraveling the role of the ghrelin gene
peptides in the endocrine pancreas. Journalof Molecular Endocrinology, 45, 107–118.
47. Tanda, M.L., Lombardi, V., Genovesi, M. et al. (2009) Plasma total and acylated ghrelin
concentrations in patients with clinical and subclinical thyroid dysfunction. Journal of
Endocrinological Investigation, 32, 74–78.
48. Mitrou, P., Boutati, E., Lambadiari, V. et al. (2010) Insulin resistance in hyperthyroidism: the
role of IL6 and TNF alpha. EuropeanJournal of Endocrinology, 162, 121–126.
49. Stanická, S., Vondra, K., Pelikánová, T. et al. (2005) Insulin sensitivity and counter-regulatory
hormones in hypothyroidism and during thyroid hormone replacement therapy. Clinical
Chemistryand Laboratory Medicine, 43, 715–720.
50. Mitrou, P., Raptis, S.A. & Dimitriadis, G. (2010) Insulin action in hyperthyroidism: a focus on
muscle and adipose tissue. EndocrineReviews, 31, 663–679.
51. Chavez, J.A. & Summers, S.A. (2010) Lipid oversupply, selective insulin resistance, and
lipotoxicity: molecular mechanisms. Biochimicaet Biophysica Acta, 1801, 252–265.
52. Erion, M.D., Cable, E.E., Ito, B.R. et al. (2007) Targeting thyroid hormone receptor-beta
agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic
index. Proceedings of theNational Academy of Sciences of the United States of America, 104,
15490–15495.
53. Roos, A., Bakker, S.J., Links, T.P. et al. (2007) Thyroid function is associated with
components of the metabolic syndrome in euthyroid subjects. Journal of Clinical
Endocrinology and Metabolism, 92, 491–496.
54. Loeb, J.N. (1996) Metabolic changes in thyrotoxicosis. In: L.E. Braverman, R.D. Utiger
eds. Werner and Ingbar's The Thyroid, 7th edn. Lippincott-Raven, Philadelphia, 687–693.
55. Lambadiari, V., Mitrou, P., Maratou, E. et al. (2010) Thyroid hormones are positively
associated with insulin resistance early in the development of type 2 diabetes. Endocrine, 39,
28–32.
56. Brenta, G. (2010) Diabetes and thyroid disorders. British Journal ofDiabetes and Vascular
Disease, 10, 172–177.
57. Potenza, M., Via, M.A. & Yanagisawa, R.T. (2009) Excess thyroid hormone and carbohydrate
metabolism.Endocrine Practice, 15, 254–262.
58. Eledrisi, M.S., Alshanti, M.S., Shah, M.F. et al. (2006) Overview on the diagnosis and
management of diabetic ketoacidosis. AmericanJournal of Medical Sciences, 331, 243–251.
59. Ramasamy, V., Kadiyala, R., Fayyaz, F. et al. (2010) Value of a baseline serum thyrotropin as
a predictor of hypothyroidism in patients with diabetes. Endocrine Practice, 14, 1–25.
60. Althausen, T.L. (1949) Hormonal and vitamin factors in intestinal
absorption. Gastroenterology, 12, 467–480.
61. Maratou, E., Hadjidakis, D.J., Kollinas, A. et al. (2009) Studies of insulin resistance in patients
with clinical and subclinical hypothyroidism. European Journal of Endocrinology, 160, 785–
790.
62. Brenta, G., Celi, F.S., Pisarev, M. et al. (2009) Acute thyroid hormone withdrawal in athyreotic
patients results in a state of insulin resistance. Thyroid, 19, 665–669.
63. Skarulis, M.C., Celi, F.S., Mueller, E. et al. (2010) Thyroid hormone induced brown adipose
tissue and amelioration of diabetes in a patient with extreme insulin resistance. Journal of
ClinicalEndocrinology and Metabolism, 95, 256–262.
64. Handisurya, A., Pacini, G. & Tura, A. (2008) Effects of T4 replacement therapy on glucose
metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clinical
Endocrinology, 69, 963–969.
65. Rotondi, N., den Elzen, W.P., Bauer, D.C. et al. (2010) Subclinical hypothyroidism and the
risk of coronary heart disease and mortality. JAMA, 304, 1365–1374.
66. Sathyapalan, T., Manuchehri, A.M., Rigby, A.S. et al. (2010) Subclinical hypothyroidism is
associated with reduced all-cause mortality in patients with type 2 diabetes. Diabetes Care,
33, e37.
67. Genuth, S. (2008) The UKPDS and its global impact. Diabetic Medicine, 25(Suppl 2), 57–62.
68. Roussel, R., Travert, F., Pasquet, B. et al. (2010) Reduction of Atherothrombosis for
Continued Health (REACH) Registry Investigators. (2010) Metformin use and mortality among
patients with diabetes and atherothrombosis.Archives of Internal Medicine, 170, 1892–1899.
69. Lim, C.T., Kola, B. & Korbonits, M. (2010) AMPK as a mediator of hormonal
signalling. Journal of Molecular Endocrinology 44, 87–97.
70. Takane, H., Shikata, E., Otsubo, K. et al. (2008) Polymorphism in human organic cation
transporters and metformin action. Pharmacogenomics, 9, 415–422.
71. Bogachus, L.D. & Turcotte, L.P. (2010) Genetic downregulation of AMPK-alpha isoforms
uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal
muscle cells. American Journal of Physiology. Cell Physiology, 299, C1549–C1561.
72. Łabuzek, K., Suchy, D., Gabryel, B. et al. (2010) Quantification of metformin by the HPLC
method in brain regions, cerebrospinal fluid and plasma of rats treated with
lipopolysaccharide. PharmacologicalReports, 62, 956–965.
73. Zolk, O. (2009) Current understanding of the pharmacogenomics of metformin. Clinical
Pharmacology and Therapeutics, 86, 595–598.
74. Vigersky, R.A., Filmore-Nassar, A. & Glass, A.R. (2006) Thyrotropin suppression by
metformin. Journal of Clinical Endocrinologyand Metabolism, 91, 225–227.
75. Isidro, M.L., Penin, M.A., Nemina, R. et al. (2007) Metformin reduces thyrotropin levels in
obese, diabetic women with primary hypothyroidism on thyroxine replacement
therapy. Endocrine, 32, 79–82.
76. Cappelli, C., Rotondi, M., Pirola, I. et al. (2009) TSH-lowering effect of metformin in type 2
diabetic patients. Differences between euthyroid, untreated hypothyroid and euthyroid on L-
T4 therapy patients. Diabetes Care, 32, 1589–1590.
77. Rezzonico, J., Rezzonico, M., Pusiol, E. et al. (2010) Metformin treatment for small benign
thyroid nodules in patients with Insulin resistance. Metabolic Syndrome and Related
Disorders, 9, 69–75.
78. Agarwal, M.M., Dhatt, G.S., Punnose, J. et al. (2006) Thyroid function abnormalities and
antithyroid antibody prevalence in pregnant women at high risk for gestational diabetes
mellitus. Gynecological Endocrinology, 22, 261–266.
79. Montaner, P., Juan, L., Campos, R. et al. (2008) Is thyroid autoimmunity associated with
gestational diabetes mellitus? Metabolism, 57, 522–525.
PROFORMA
Swelling in neck Fatigue
Hoarse voice Menstrual disturbances
Constipation
Weight gain&  reduced appetite h/o  diabetes
Cold intolerance h/o  hypothyroidism
Pallor CVS
Icterus RS
Pedal edema P/A
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Pulse BP
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AGE /SEX:
OCCUPATION:
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IP NO/OP NO:
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DATE OF DISCHARGE
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TC DC ESR HB PCV MCV MCH MCHC PLT
SUGAR
FBS      PPBS
UREA CR Na+ K+ HCO3- Cl-
TB DB SGOT SGPT SAP TOTAL
PROTEINS
ALBUMIN
TSH FT3 FT4
HBA1C
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INFORMED CONSENT
DISSERTATION TOPIC: “A STUDY ON PREVALENCE OF HYPOTHYROIDISM
(CLINICAL/SUBCLINICAL) IN DIABETES MELLITUS AND CORRELATION OF HbA1C LEVELS WITH TSH
LEVELS”
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI
NAME AND ADDRESS OF PATIENT:
I, _____________________ have been informed about the details of the study in my own
language.
I have completely understood the details of the study.
I am aware of the possible risks and benefits, while taking part in the study.
I understand that I can withdraw from the study at any point of time and even then, I will
continue to receive the medical treatment as usual.
I understand that I will not get any payment for taking part in this study.
I will not object if the results of this study are getting published in any medical journal,
provided my personal identity is not revealed.
I know what I am supposed to do by taking part in this study and I assure that I would
extend my full co-operation for this study.
Name and Address of the Volunteer:
Signature/Thumb impression of the Volunteer
Date:
Witnesses:
(Signature, Name & Address)
Date:
Name and signature of investigator:
சா் கைரேநா உ ளவாக்ளைடேய ைஹேபாைதரா ேநாய
தா க ைத , இர த தி HbA1c ம TSH அள களைடேயஆன
ெதாடா்ைப அறிவத கானஓ ஆ
ஆ வாள :ம . திலி ஹ ர ெவ ல ேதா ,
நிைலப டேம ப மாணவ ,
ெபா ம வ ப டப .
வழிகா :ேபராசி ய ம .க. தர தி ,
ெபா ம வேபராசி ய ,அர டா லிம வமைன.
யஒ த ப வ
ெபய : வய : உ ள எ :
இ த ம வ ஆ வ  வவர க  என  வள க ப ட . எ ைடய
ச ேதக கைள ேக க ,அத கான த தவள க கைள ெபற  வா பள க ப ட .
நா  இ வா வ  த ன ைசயாக தா  ப ேக கிேற . எ த காரண தினா ,எ தக ட தி ,
எ த ச டசி க  இ றி இ த ஆ வலி  வலகி ெகா ளலா  எ  அறி ெகா ேட .
நா  ஆ வலி  வலகி ெகா டா  ஆ வாள  எ ைடய ம வ
அறி ைககைள பா பத ேகா அ ல  உபேயாகி கேவா எ  அ மதி ேதைவய ைல என
அறி ெகா ேட .எ ைன ப றிய தகவ க  இரகசியமாக பா கா க ப  எ பைத
அறிேவ .
இ த ஆ வ ல  கிைட  தகவ கைள  ப ேசாதைன கைள .ஆ வாள  அவ
வ ப தி ேக ப எ வதமாக பய ப தி ெகா ள , அதைனப ர க மன ட
ச மதி கிேற .
இ த ஆ வ  ப  ெகா ள  ஒ ெகா கிேற . என ெகா க ப ட அறி ைரகள ப
நட ெகா வ ட , ஆ வாள  உ ைம ட  இ ேப  எ  உ தியள கிேற .எ
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அைத ெத வ ேப  என உ தி கிேற .
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மன ட  ச மதி கிேற .
இ ப
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ெவ ல ேதா )
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ேநா க ைத , ைறகைள ,இதனா  ஏ ப  ப வைள கைள  ந க  அறி  ெகா ள
ஆ வாள  அள  தகவ :
உ க  ேநாய  வரலா , உ கள  உட ப ேசாதைன  ெதளவாக  வ வாக
பதி ெச ய ப .
இ த ஆ வ க  ம வ காரண க காக , ம வ க வ காக
பய ப த ப . இ த ஆ  ப றிய ச ேதக க  உ ய ைறய  வள கமள க ப .
த கைள ப றிய தகவ க  இரகசியமாக பா கா க ப .
இ த ஆ வ  இ  எ ேபா  ேவ மானா  தா க  எ வத னறிவ ப றி , எ வ த
ச டசி க  இ றி வலகி ெகா ளலா .
இ த ஆ வ  ப ேக மா  ேக ெகா கிேற .
ந றி,
ஆ வாள  ைகெயா ப ேநாயாளய  ைகெயா ப
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ETHICAL COMMITTEE APPROVAL
MASTER CHART
SlNo Age Sex H/Odiabetes
H/O
hypot
FBS
(MG/DL)
PPBS
(MG/DL)
HbA1c
(FV) (%)
TSH(FV)
(mIU/L)
TSH
(AT)
Hba1c
(AT)
1 54 F YES(5 YRS) NO 102 186 8 6 5 7
2 58 F YES(6YRS) NO 96 156 7.5 6.8 4.8 6
3 62 F YES(4YRS) NO 100 139 8.5 7 5.8 8
4 55 M YES(7YRs) NO 123 198 8.3 7.2 6.5 7.9
5 50 F YES(3YRS) NO 109 176 6.5 5.5 5.2 6.5
6 56 F YES(5 YRS) NO 114 154 7 6 5.4 6.8
7 57 F YES(8YRS) NO 122 201 8.5 6.7 6 7.7
8 47 M YES(4YRS) NO 103 139 7.2 4.8
9 50 M YES(5YRS) NO 121 178 7.8 5.9 5.2 7.3
10 65 F YES(10YRS) YES 134 202 8.4 7.8 7.2 7.5
11 49 M YES(3YRS) NO 100 130 6.7 5.7 5.3 6.6
12 51 F YES(5YRS) YES 98 129 6.9 7.8 7.7 6.2
13 56 F YES(6YRS) NO 104 164 7.1 5.9 5.4 6.9
14 55 F YES(7YRS) NO 108 156 7.4 5.7 5.4 7
15 60 M YES(9YRS) NO 106 143 7 5.5 5 6.9
16 54 F YES(6YRS) NO 101 132 7 5.3 5.2 7
17 61 M YES(11YRS) NO 120 190 8 6.1 5.9 7.5
18 67 F YES(13YRS) YES 119 176 8.2 6.8 6.7 7.8
19 58 F YES(7YRS) NO 110 138 7.5 5.8 5.7 7.2
20 49 F YES(4YRS) NO 108 140 7.3 4.9
21 43 F YES(3YRS) NO 94 120 7 5.3 5 7
22 62 M YES(12YRS) NO 124 190 8.8 6 5.5 8.2
23 56 F YES(6YRS) NO 105 149 7.6 5.8 5.4 7.3
24 55 F YES(5YRS) NO 103 145 7.4 5.5 5.2 7
25 58 M YES(8YRS) NO 117 168 7.5 5.8 5.5 7.2
26 52 F YES(6YRS) NO 106 134 7.3 5.5 5.3 7.1
27 51 F YES(3YRS) NO 109 140 7.6 4.8
28 52 F YES(5YRS) NO 110 164 7.8 5.9 5.6 7.5
29 57 F YES(6YRS) NO 118 176 7.9 6 5.8 7.6
30 58 M YES(5YRS) NO 120 164 7.6 4
31 57 F YES(6YRS) NO 118 172 7.4 5.6 5.2 7.2
32 64 M YES(5YRS) NO 116 166 7.5 5.4 5.2 7.2
33 55 F YES(4YRS) NO 123 185 7.6 5.5 5.2 7.3
34 57 M YES(9YRS) NO 121 175 7.8 4.7
35 58 F YES(7YRS) NO 115 154 7 4.5
36 56 M YES(6YRS) NO 113 145 7.4 5.6 5.4 7.2
37 58 F YES(7YRS) NO 121 167 7.5 4.9
38 57 M YES(8YRS) NO 124 163 7.6 5.6 5.4 7.2
39 58 F YES(7YRS) NO 113 143 7.5 4.3
40 59 F YES(6YRS) NO 112 154 7.6 5.6 5.3 7.3
41 56 F YES(5YRS) YES 122 178 7.7 6.5 6.4 7.5
42 58 M YES(7YRS) NO 134 206 8.7 5.8 5.5 8.3
43 47 F YES(3YRS) NO 110 156 7 5.5 5.2 6.8
44 49 F YES(5YRS) NO 100 140 7 4.7
45 53 F YES(4YRS) NO 101 134 7.4 5.4 5.2 7.2
46 56 F YES(5YRS) YES 122 178 7.6 5.8 5.7 7.2
47 53 F YES(5YRS) NO 114 154 7.5 5.5 5.3 7.3
48 54 M YES(5YRS) NO 112 153 7.7 5.8 5.4 7.4
49 59 F YES(7YRS) NO 119 156 7.5 5.4 5.2 7.2
50 60 M YES(10YRS) NO 120 180 7.9 5.8 5.4 7.5
KEY TO MASTER CHART
FBS : Fasting Blood Sugar
PPBS : Post Prandial Blood Sugar
TSH : Thyroid Stimulating Hormone
HbA1c : Glycosylated Haemoglobin
Hypot : Hypothyroidism
AT : After thyroxine treatment of three months
